Imiti igezweho yo kurwara

Ku ya 15 Gicurasi, Vanda Pharmaceuticals, isosiyete ikora ibijyanye n’ibinyabuzima muri Amerika, yatangaje ko ubushakashatsi bwa kabiri bw’icyiciro cya gatatu cy’imiti mishya ya Tradipitant (tradipitant) yo kuvura indwara ziterwa n’imitsi (cyane cyane indwara zigenda) bwageze ku musaruro ushimishije.
Tradipitant ni neurokinin-1 (NK1) reseptor antagonist yakozwe na Eli Lilly. Vanda yabonye uburenganzira bwiterambere ryisi yose ya Tradipitant binyuze muburenganzira muri Mata 2012.
Kugeza ubu, Vanda yashyizeho Tradipitant yerekana ibimenyetso nka atopic dermatitis pruritus, gastroparesis, indwara nshya ya coronavirus, indwara ziterwa no kugenda, ibiyobyabwenge, phobia, hamwe no kutarya.
Ubu bushakashatsi bwo mu cyiciro cya 3 bwarimo abarwayi 316 bafite uburwayi bwimitsi bafite amateka yuburwayi bwimitsi, bavuwe na mg 170 Tradipitant, 85 mg Tradipitant, cyangwa umwanya wabo mugihe cyurugendo rwubwato.
Abitabiriye ubushakashatsi bose bafite amateka yo kurwara inyanja. Iherezo ryibanze ryubushakashatsi ni ingaruka zumucuruzi (mg 170) kuruka. Ibyingenzi byingenzi byanyuma ni: (1) ingaruka zumucuruzi (85 mg) kuruka; (2) ingaruka z'umucuruzi mukurinda isesemi ikabije no kuruka.
Biravugwa ko uburwayi bwo kugenda bukomeza gukenerwa mu buvuzi. Ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA) nticyemeje imiti mishya yo kuvura indwara zigenda mu myaka irenga 40 kuva yemera scopolamine (agapira ka transdermal gashyizwe inyuma y ugutwi) mu 1979.

Hashingiwe ku mibare yavuye mu bushakashatsi bubiri bw'icyiciro cya gatatu, Vanda izatanga icyifuzo cyo kwamamaza ku mucuruzi muri FDA kugira ngo ivure indwara zigenda mu gihembwe cya kane cya 2024.